What are the best treatments for Birt-Hogg-Dubé syndrome?

TL;DR: There is currently no curative medical therapy for Birt-Hogg-Dubé syndrome (BHD), so treatment focuses on the proactive surveillance of renal tumors and the management of pulmonary complications. The standard of care involves lifelong monitoring through imaging and surgical intervention when renal tumors reach a specific size threshold to prevent malignancy.

What is the current approach to managing Birt-Hogg-Dubé syndrome?

Because Birt-Hogg-Dubé syndrome is a rare genetic disorder caused by mutations in the FLCN gene, management is primarily centered on surveillance rather than systemic drug treatment. Because individuals with Birt-Hogg-Dubé syndrome have a significantly elevated risk of developing renal cell carcinoma (RCC)—estimated at approximately 7 times that of the general population—the core of clinical management is early detection. Physicians typically recommend annual or biennial abdominal imaging, such as MRI (preferred to minimize radiation exposure) or CT scans, to monitor for the development of renal masses.

What are the primary treatment options for Birt-Hogg-Dubé syndrome?

Treatment for Birt-Hogg-Dubé syndrome is highly personalized and depends on the specific manifestations present in the patient. Current guidelines suggest the following clinical interventions:

• Renal Surgery: Nephron-sparing surgery (partial nephrectomy) is the gold standard when a renal tumor reaches approximately 3 cm in diameter. This approach removes the tumor while preserving as much healthy kidney function as possible.


• Pulmonary Management: Patients with Birt-Hogg-Dubé syndrome are at high risk for spontaneous pneumothorax (collapsed lung) due to the presence of pulmonary cysts. Management involves surgical pleurodesis or thoracoscopy if recurrent pneumothorax occurs.


• Dermatological Care: Cutaneous manifestations, such as fibrofolliculomas, are benign but can be cosmetically distressing. Treatments may include laser ablation, curettage, or excision, though recurrence is common.

Are there emerging medications for Birt-Hogg-Dubé syndrome?

Currently, there are no FDA-approved medications specifically indicated to treat or reverse the underlying genetic cause of Birt-Hogg-Dubé syndrome. However, clinical researchers are investigating the mTOR signaling pathway, which is often dysregulated in Birt-Hogg-Dubé syndrome due to FLCN protein deficiency. Some clinical trials have explored the use of mTOR inhibitors, such as rapamycin (Sirolimus) or everolimus (Afinitor), to manage tumor growth, but these are generally considered experimental and are not yet established as standard-of-care treatments.

Which specialists should be on my care team?

Given the multisystemic nature of this condition, a multidisciplinary care team is essential for patients with Birt-Hogg-Dubé syndrome. Your team should ideally include:

• Urologist: To oversee renal surveillance and perform nephron-sparing surgeries.


• Pulmonologist: To monitor lung health, assess cyst burden, and manage the risk of pneumothorax.


• Clinical Geneticist: To provide genetic counseling for the patient and at-risk family members.


• Dermatologist: To provide management for skin lesions and monitor for rare instances of basal cell carcinoma.


• Radiologist: To provide expert interpretation of longitudinal imaging studies.

Next steps

• Consult with a geneticist to confirm your FLCN mutation status and discuss cascade testing for family members.


• Establish a regular surveillance schedule with a urologist familiar with hereditary renal cancer syndromes.


• Connect with the 114 members of the DiseaseMaps.org community to share experiences and coping strategies.


• Avoid smoking, as it may exacerbate pulmonary cyst formation and increase the risk of pneumothorax.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Birt-Hogg-Dubé syndrome.


• Orphanet: Birt-Hogg-Dubé syndrome (ORPHA:124).


• OMIM (Online Mendelian Inheritance in Man): Birt-Hogg-Dubé Syndrome; BHD (#135150).


• The BHDS Foundation: Clinical guidelines and patient resources.